July 15, 2016
TD2’s VP of Nonclinical Operations, Paul Gonzales, will be presenting at the upcoming 4th Annual Tumor Models – Boston (www.tumor-models.com) on Wednesday, July 20th. The topic of the presentation is The Role of the Gut Microbiome on the Anti-Tumor Response of Immune Checkpoint Inhibitors in a Syngeneic Murine Model of HPV-Associated Cancer.
Contact us if you’re interested in a copy of the presentation.
CAR T-cell therapy originated in the late 1980s, first-generation constructs lacked adequate co-stimulatory signaling, causing poor CAR T-cell ...
Developing cancer therapies is an incredibly complex, costly, and highly regulated journey. To navigate this challenging terrain, pharmaceutical and ...
Bone cancers and soft tissue sarcomas represent a diverse group of rare malignancies arising from mesenchymal tissues including bone, muscle, fat, ...
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
© 2026 Translational Drug Development. All Rights Reserved. Terms and Conditions | Privacy Policy
